FI3737423T3 - Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon - Google Patents

Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon Download PDF

Info

Publication number
FI3737423T3
FI3737423T3 FIEP19701018.4T FI19701018T FI3737423T3 FI 3737423 T3 FI3737423 T3 FI 3737423T3 FI 19701018 T FI19701018 T FI 19701018T FI 3737423 T3 FI3737423 T3 FI 3737423T3
Authority
FI
Finland
Prior art keywords
sequence
tcu
nucleotides
seo
vector
Prior art date
Application number
FIEP19701018.4T
Other languages
English (en)
Finnish (fi)
Inventor
Robin Ali
Takaaki Matsuki
Alexander Smith
Anastasios Georgiadis
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Application granted granted Critical
Publication of FI3737423T3 publication Critical patent/FI3737423T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP19701018.4T 2018-01-12 2019-01-14 Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon FI3737423T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1800546.2A GB201800546D0 (en) 2018-01-12 2018-01-12 Treatment
PCT/GB2019/050092 WO2019138250A1 (en) 2018-01-12 2019-01-14 Compositions and methods for treating retinal disorders

Publications (1)

Publication Number Publication Date
FI3737423T3 true FI3737423T3 (fi) 2024-11-02

Family

ID=61256183

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19701018.4T FI3737423T3 (fi) 2018-01-12 2019-01-14 Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon

Country Status (26)

Country Link
US (2) US11680276B2 (cg-RX-API-DMAC7.html)
EP (1) EP3737423B1 (cg-RX-API-DMAC7.html)
JP (1) JP7289306B2 (cg-RX-API-DMAC7.html)
KR (1) KR102786552B1 (cg-RX-API-DMAC7.html)
CN (1) CN111936172A (cg-RX-API-DMAC7.html)
AU (1) AU2019206314B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014191A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088079A1 (cg-RX-API-DMAC7.html)
DK (1) DK3737423T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091655A1 (cg-RX-API-DMAC7.html)
ES (1) ES2988499T3 (cg-RX-API-DMAC7.html)
FI (1) FI3737423T3 (cg-RX-API-DMAC7.html)
GB (1) GB201800546D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20241483T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068987T2 (cg-RX-API-DMAC7.html)
IL (1) IL275985A (cg-RX-API-DMAC7.html)
LT (1) LT3737423T (cg-RX-API-DMAC7.html)
MX (1) MX2020007366A (cg-RX-API-DMAC7.html)
PH (1) PH12020551071A1 (cg-RX-API-DMAC7.html)
PL (1) PL3737423T3 (cg-RX-API-DMAC7.html)
PT (1) PT3737423T (cg-RX-API-DMAC7.html)
RS (1) RS66227B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006618PA (cg-RX-API-DMAC7.html)
SI (1) SI3737423T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400410T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019138250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906815A1 (en) 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
GB2584664B (en) * 2019-06-10 2023-05-24 Newcells Biotech Ltd Improved retinal organoids and methods of making the same
CN113025616B (zh) * 2021-04-21 2023-05-02 中国热带农业科学院橡胶研究所 一种橡胶树泛素基因启动子proHbUBI2及其克隆与应用
WO2022246089A1 (en) * 2021-05-20 2022-11-24 Artema Therapeutics, Inc. Kcnv2 variants and their use
CA3225080A1 (en) * 2021-07-14 2023-01-19 Anastasios GEORGIADIS Kcnv2 gene therapy
WO2023039175A2 (en) * 2021-09-09 2023-03-16 Applied Genetic Technologies Corporation Predictors of achromatopsia treatment efficacy
WO2026150224A1 (en) 2024-12-30 2026-07-16 MeiraGTx Ocular UK Limited Modified adeno-associated virus (aav) viral capsid proteins and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
CN103608455B (zh) * 2011-01-07 2019-01-15 应用遗传科技公司 用于治疗色盲和其它疾病的启动子、表达盒、载体、药盒和方法
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
FI3265178T3 (fi) * 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
WO2017144080A1 (en) * 2016-02-23 2017-08-31 Eyeserv Gmbh Gene therapy for the treatment of a disease of retinal cone cells

Also Published As

Publication number Publication date
SI3737423T1 (sl) 2025-03-31
DK3737423T3 (da) 2024-10-21
PH12020551071A1 (en) 2021-09-06
ES2988499T3 (es) 2024-11-20
US20200392536A1 (en) 2020-12-17
EP3737423A1 (en) 2020-11-18
US11680276B2 (en) 2023-06-20
EA202091655A1 (ru) 2020-11-20
GB201800546D0 (en) 2018-02-28
SMT202400410T1 (it) 2025-01-14
CN111936172A (zh) 2020-11-13
US12467066B2 (en) 2025-11-11
SG11202006618PA (en) 2020-08-28
KR20200141435A (ko) 2020-12-18
MX2020007366A (es) 2020-09-03
PT3737423T (pt) 2024-10-03
AU2019206314B2 (en) 2025-02-13
PL3737423T3 (pl) 2025-01-27
CA3088079A1 (en) 2019-07-18
IL275985A (en) 2020-08-31
HRP20241483T1 (hr) 2025-01-03
WO2019138250A1 (en) 2019-07-18
HUE068987T2 (hu) 2025-02-28
AU2019206314A1 (en) 2020-08-13
JP2021510301A (ja) 2021-04-22
NZ766316A (en) 2024-05-31
RS66227B1 (sr) 2024-12-31
EP3737423B1 (en) 2024-09-18
US20240067989A1 (en) 2024-02-29
JP7289306B2 (ja) 2023-06-09
BR112020014191A2 (pt) 2022-02-22
LT3737423T (lt) 2024-11-25
KR102786552B1 (ko) 2025-03-26

Similar Documents

Publication Publication Date Title
HRP20241483T1 (hr) Sastavi i postupci za liječenje poremećaja mrežnice
JP2019089787A5 (cg-RX-API-DMAC7.html)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2014512171A5 (cg-RX-API-DMAC7.html)
FI3442600T3 (fi) Adeno-assosioidulla virusvektorilla b-sarkoglykaanin ja mikro-rna-29:n toimittaminen ja lihasdystrofian hoito
JP2021510301A5 (cg-RX-API-DMAC7.html)
US10413598B2 (en) Factor IX gene therapy
JP2019513779A5 (cg-RX-API-DMAC7.html)
JP2019513399A5 (cg-RX-API-DMAC7.html)
HRP20201831T1 (hr) Optimizirani promoter rpe65 i kodirajuće sekvence
AU2019250249A1 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
FI3851537T3 (fi) Hyperbilirubinemian hoito
JP2017518271A5 (cg-RX-API-DMAC7.html)
JP2018510620A5 (cg-RX-API-DMAC7.html)
MX2021010134A (es) Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn.
JP2015523379A5 (cg-RX-API-DMAC7.html)
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
WO2020223362A8 (en) Compositions useful for treatment of pompe disease
JP2018535696A5 (cg-RX-API-DMAC7.html)
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2018509154A5 (cg-RX-API-DMAC7.html)
JP2017506230A5 (cg-RX-API-DMAC7.html)
JP2017523239A5 (cg-RX-API-DMAC7.html)
IL308645A (en) Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
JP2021502978A5 (cg-RX-API-DMAC7.html)